News & Updates
Filter by Specialty:
![[HKU Medical Grand Rounds] Angels and demons: Immunotherapy for treatment of advanced hepatocellular carcinoma](https://sitmspst.blob.core.windows.net/images/articles/angels-and-demons-5b3b3859-410a-440e-91c5-965a92c3f735-square.jpg)
Adalimumab concentrations negatively linked to inflammatory markers in RA
A negative association exists between adalimumab (ADA) concentrations and markers of inflammatory disease activity in rheumatoid arthritis (RA), including interleukin 6 (IL-6), reveals a study. Notably, ADA concentrations from 5 to 7 mg/L over the dose interval seem to contribute to better disease control.
Adalimumab concentrations negatively linked to inflammatory markers in RA
22 Jul 2024
Novel agent plus ritonavir show favourable signals for mild-to-moderate COVID-19
A combination regimen comprising the novel agent GST-HG171 (also known as atilotrelvir) and ritonavir improves clinical symptom recovery and viral clearance in low-risk vaccinated adults with mild-to-moderate COVID-19, findings from a pivotal phase II/III study have shown.
Novel agent plus ritonavir show favourable signals for mild-to-moderate COVID-19
10 Jul 2024
Neoadjuvant cycles do not alter perioperative nivolumab benefit in resectable NSCLC
Treatment with nivolumab plus chemotherapy before surgery followed by nivolumab after surgery yields superior outcomes for patients with resectable nonsmall cell lung cancer (NSCLC) as compared with placebo plus chemotherapy, regardless of the number of completed neoadjuvant cycles, according to an exploratory analysis of the CHECKMATE 77T trial.
Neoadjuvant cycles do not alter perioperative nivolumab benefit in resectable NSCLC
02 Jul 2024
Subcutaneous atezolizumab favoured over intravenous infusion
Nonsmall cell lung cancer (NSCLC) patients with high PD-L1 expression appear to show a strong preference for receiving atezolizumab subcutaneously rather than intravenously.
